2-(biphenyl-4-yl)propan-2-yl methyl[2-(methylamino)ethyl]carbamate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(biphenyl-4-yl)propan-2-yl methyl[2-(methylamino)ethyl]carbamate
• 英文别名: 2-(4-phenylphenyl)propan-2-yl N-methyl-N-[2-(methylamino)ethyl]carbamate
• 化学式: C₂₀H₂₆N₂O₂
• 分子量: 326.439
• InChiKey: RWYXAMWRKLUOLK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(biphenyl-4-yl)propan-2-yl methyl[2-(methylamino)ethyl]carbamate 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 、 甲苯 为溶剂， 反应 121.0h， 生成 2-(4-phenylphenyl)propan-2-yl N-methyl-N-[2-[methyl-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethoxy]carbonylamino]ethyl]carbamate
  参考文献：
  名称：

  [EN] PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF
  [FR] COMPOSÉS PEPTIDOMIMÉTIQUES ET CONJUGUÉS ANTICORPS-MÉDICAMENT DE CEUX-CI

  摘要：

  公开号：

  WO2015095223A3
• 作为产物：
  描述：

  2-(4-联苯基)-2-丙醇 在 吡啶 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 生成 2-(biphenyl-4-yl)propan-2-yl methyl[2-(methylamino)ethyl]carbamate
  参考文献：
  名称：

  WO2020065408A5

  摘要：

  公开号：

  WO2020065408A5

文献信息

• [EN] FUNCTIONALIZED MORPHOLINYL ANTHRACYCLINE DERIVATIVES<br/>[FR] DÉRIVÉS DE MORPHOLINYLANTHRACYCLINE FONCTIONNALISÉS
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2016071418A1

  公开（公告）日：2016-05-12

  The present invention relates to new functionalized morpholinyl anthracycline derivatives which have cytotoxic activity and are useful in treating diseases such as cancer, cellular proliferation disorders and viral infections. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising them and methods of treating diseases utilizing such compounds, or the pharmaceutical compositions containing them. The invention also relates to the use of these derivatives in the preparation of conjugates. The morpholinyl anthracycline derivatives are of the formula Ant-L-W-Z-RM (I) wherein RM is null or a reactive moiety; Z is null or a peptidic, non peptidic or hybrid - peptidic and non peptidic - linker; W is null or a self-immolative system, comprising one or more self-immolative groups; L is null or a conditionally-cleavable moiety; Ant is an anthracycline moiety selected from the formulas (II), (III), (IV) and (V), wherein the wavy line indicates the attachment to the conditionally-cleavable moiety L, or to the self-immolative system W, or to the linker Z, or to the reactive moiety RM; provided that at least one of L, W, Z and RM is not null; R1 is halogen or NR4R5; R2 is OR6, NR7R8 or an optionally substituted group selected from straight or branched C1C4alkyl-, NR7R8-C1C4alkyl- and R60-C1C4alkyl-; R4 and R5 are independently hydrogen, a monosubstituted-benzyl, a disubstituted-benzyl, or an optionally substituted group selected from straight or branched C1-C6alkyl, NR7R8-C1-C6alkyl-, R60-C1-C6alkyl-, R7R8N-C1-C6alkylcarbonyl-, R60-C1-C6alkylcarbonyl-, R7R8N-C1-C6alkoxycarbonyl- and R60-C1-C6alkoxycarbonyl-; or R4 and R5, taken together with the nitrogen atom to which they are bound, form a heterocyclyl substituted with R4', wherein R4' is hydrogen or a group selected from straight or branched C1-C6alkyl and NR7R8-C1-C6alkyl-; R15 is null or an optionally substituted bivalent group selected from -NR7-C1-C6alkyl*, -O-C1-C6alkyl*, -NR7-C1-C6alkylcarbonyl*, -O-C1-C6alkylcarbonyl*, -NR7-C1-C6alkoxycarbonyl* and -O-C1-C6alkoxycarbonyl*, wherein * indicates the point of attachment to -NH-Ant; R6, R7 and R8 are independently hydrogen or an optionally substituted straight or branched C1-C6alkyl; or a pharmaceutically acceptable salt thereof.

  本发明涉及具有细胞毒活性并用于治疗癌症、细胞增殖紊乱和病毒感染等疾病的新功能化吗啉基蒽环素衍生物。本发明还提供了制备这些化合物的方法、包含它们的药物组合物以及利用这些化合物或含有它们的药物组合物治疗疾病的方法。该发明还涉及将这些衍生物用于制备共轭物的用途。吗啉基蒽环素衍生物的化学式为Ant-L-W-Z-RM（I），其中RM为空或为反应性基团；Z为空或为肽、非肽或混合肽和非肽连接物；W为空或为自解离系统，包括一个或多个自解离基团；L为空或为条件可切割基团；Ant为从化学式（II）、（III）、（IV）和（V）中选择的蒽环素基团，其中波浪线表示与条件可切割基团L、自解离系统W、连接物Z或反应性基团RM的连接；但要求至少有一个L、W、Z和RM不为空；R1为卤素或NR4R5；R2为OR6、NR7R8或从直链或支链C1-C4烷基、NR7R8-C1-C4烷基和R60-C1-C4烷基中选择的可选择取代基团；R4和R5独立地为氢、单取代苄基、双取代苄基或从直链或支链C1-C6烷基、NR7R8-C1-C6烷基、R60-C1-C6烷基、R7R8N-C1-C6烷基羰基、R60-C1-C6烷基羰基、R7R8N-C1-C6烷氧羰基和R60-C1-C6烷氧羰基中选择的可选择取代基团；或R4和R5与它们结合的氮原子一起形成与R4'取代的杂环烷基，其中R4'为氢或从直链或支链C1-C6烷基和NR7R8-C1-C6烷基中选择的基团；R15为空或从-NR7-C1-C6烷基*、-O-C1-C6烷基*、-NR7-C1-C6烷基羰基*、-O-C1-C6烷基羰基*、-NR7-C1-C6烷氧羰基*和-O-C1-C6烷氧羰基*中选择的可选择取代的二价基团，其中*表示与-NH-Ant的连接点；R6、R7和R8独立地为氢或可选择取代的直链或支链C1-C6烷基；或其药学上可接受的盐。
• [EN] THIENO[2,3-e]INDOLE DERIVATIVES AS NEW ANTITUMOR AGENTS<br/>[FR] DÉRIVÉS DE THIÉNO[2,3-E]INDOLE EN TANT QUE NOUVEAUX AGENTS ANTITUMORAUX
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2015044003A1

  公开（公告）日：2015-04-02

  The present invention relates to a novel class of alkylating agents comprising a thieno[2,3-e]indole moiety tethered to a DNA-binding moiety, which have cytotoxic activity and are useful in treating diseases such as cancer, cellular proliferation disorders and viral infections. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising them and methods of treating diseases utilizing such compounds or the pharmaceutical composition containing them. The invention also relates to the use of this novel class of alkylating agents in the preparation of conjugates.

  本发明涉及一类新型的烷基化剂，其包含与DNA结合基团相连的噻吩并[2,3-e]吲哚部分，具有细胞毒性活性，并可用于治疗癌症、细胞增殖障碍和病毒感染等疾病。本发明还提供了制备这些化合物的方法、包含这些化合物的药物组合物以及使用这些化合物或含有这些化合物的药物组合物治疗疾病的方法。本发明还涉及这类新型烷基化剂在制备缀合物中的用途。
• [EN] NEW ALKYLATING AGENTS<br/>[FR] NOUVEAUX AGENTS ALKYLANTS
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2013149948A1

  公开（公告）日：2013-10-10

  The present invention relates to a novel class of alkylating agents comprising a thieno-indole moiety linked to a DNA-binding moiety, which have cytotoxic activity and are useful in treating diseases such as cancer, cellular proliferation disorders and viral infections. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising them and methods of treating diseases utilizing such compounds or the pharmaceutical composition containing them. The invention also relates to the use of this novel class of alkylating agents in the preparation of conjugates.

  本发明涉及一种新型的烷基化剂类别，包括与DNA结合基团连接的噻吩-吲哚基团，具有细胞毒活性，并可用于治疗癌症、细胞增殖紊乱和病毒感染等疾病。本发明还提供了制备这些化合物的方法、包含它们的药物组合物以及利用这些化合物或含有它们的药物组合物治疗疾病的方法。该发明还涉及将这种新型烷基化剂类别用于制备共轭物的用途。
• ALKYLATING AGENTS
  申请人：NERVIANO MEDICAL SCIENCES S.R.L.

  公开号：US20150051154A1

  公开（公告）日：2015-02-19

  The present invention relates to a novel class of alkylating agents comprising a thieno-indole moiety linked to a DNA-binding moiety, which have cytotoxic activity and are useful in treating diseases such as cancer, cellular proliferation disorders and viral infections. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising them and methods of treating diseases utilizing such compounds or the pharmaceutical composition containing them. The invention also relates to the use of this novel class of alkylating agents in the preparation of conjugates.

  本发明涉及一种新型的烷基化剂类别，包括与DNA结合基团相连的噻吩-吲哚基团，具有细胞毒活性，并可用于治疗癌症、细胞增殖紊乱和病毒感染等疾病。本发明还提供了制备这些化合物的方法、包含它们的药物组合物以及利用这些化合物或含有它们的药物组合物治疗疾病的方法。该发明还涉及将这种新型烷基化剂类别用于制备共轭物的用途。
• [EN] Anti-CD79b Antibodies, Drug Conjugates, and Applications thereof<br/>[FR] ANTICORPS ANTI-CD79B, CONJUGUÉS ANTICORPS-MÉDICAMENTS ET UTILISATIONS ASSOCIÉES
  申请人：NEWBIO THERAPEUTICS INC

  公开号：WO2020088587A1

  公开（公告）日：2020-05-07

  Disclosed herein is an anti-CD79b antibody or antigen-binding fragment thereof, a drug conjugate thereof and use thereof. The anti-CD79b antibody or antigen-binding fragment thereof herein comprises: HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and LCDR3 comprising the amino acid sequence of SEQ ID NO: 6.

  本文披露了一种抗CD79b抗体或其抗原结合片段，以及药物结合物和使用方法。本文中的抗CD79b抗体或其抗原结合片段包括：HCDR1包括序列号为SEQ ID NO: 1的氨基酸序列；HCDR2包括序列号为SEQ ID NO: 2的氨基酸序列；HCDR3包括序列号为SEQ ID NO: 3的氨基酸序列；LCDR1包括序列号为SEQ ID NO: 4的氨基酸序列；LCDR2包括序列号为SEQ ID NO: 5的氨基酸序列；以及LCDR3包括序列号为SEQ ID NO: 6的氨基酸序列。